NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - PECELEGANAN SPRAY APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TECOTABART VEDOTIN “CLDN18.2 ADC”

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 17 JUNE 2026

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE II CLINICAL TRIAL OF TQC2938 “ST2 MONOCLONAL ANTIBODY” PRESENTED AT EAACI 2026